Ovid Therapeutics (OVID) Stock Forecast & Price Target

→ Historic NVIDIA partnership could send this tiny AI stock soaring... (From Behind the Markets) (Ad)

$0.79

0.00 (0.00%)

(As of 06/18/2024 ET)

Ovid Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 6 Analyst Ratings

Consensus Price Target

$4.70
496.52% Upside

High Forecast	$8.00
Average Forecast	$4.70
Low Forecast	$1.20

Type	Current Forecast 6/20/23 to 6/19/24	1 Month Ago 5/21/23 to 5/20/24	3 Months Ago 3/22/23 to 3/21/24	1 Year Ago 6/20/22 to 6/20/23
Consensus Rating	Moderate Buy	Moderate Buy	Buy	Hold
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	5 Buy rating(s)	2 Buy rating(s)	0 Buy rating(s)
Hold	2 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$4.70	$8.08	$9.50	$2.50
Forecasted Upside	496.52% Upside	144.09% Upside	166.11% Upside	18.20% Upside

Get Ovid Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter.

Ad Behind the Markets

Historic NVIDIA partnership could send this tiny AI stock soaring...

After striking partnerships with trillion-dollar chipmaker NVIDIA... ARM surged over 60% in a week... Who's next?

Click here to discover the name and ticker symbol >>>

OVID Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

OVID Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Ovid Therapeutics Stock vs. The Competition

Type	Ovid Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.67	2.70	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	496.52% Upside	1,067.73% Upside	11.31% Upside
News Sentiment Rating	Negative News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
6/18/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$11.00 ➝ $5.00	+517.20%
6/18/2024	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$9.00 ➝ $3.00	+261.44%
6/18/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$3.50 ➝ $1.20	+44.58%
6/18/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Selvaraju Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$9.00 ➝ $3.00	+279.94%
6/18/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
4/5/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$8.00	+162.29%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 06:10 AM ET.

OVID Forecast - Frequently Asked Questions

What is Ovid Therapeutics's stock forecast and purchase recommendation?: According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Ovid Therapeutics is $4.70, with a high forecast of $8.00 and a low forecast of $1.20. The consensus rating for Ovid Therapeutics stock is Moderate Buy based on the current 2 hold ratings and 4 buy ratings for OVID. Learn more on OVID's analyst rating history.
Do Wall Street analysts like Ovid Therapeutics more than its competitors?: Analysts like Ovid Therapeutics less than other "medical" companies. The consensus rating score for Ovid Therapeutics is 2.67 while the average consensus rating score for "medical" companies is 2.70. Learn more on how OVID compares to other companies.
Is Ovid Therapeutics being downgraded by Wall Street analysts?: Over the previous 90 days, Ovid Therapeutics's stock had 1 downgrade by analysts.

Does Ovid Therapeutics's stock price have much upside?: According to analysts, Ovid Therapeutics's stock has a predicted upside of 218.75% based on their 12-month stock forecasts.
What analysts cover Ovid Therapeutics?: Ovid Therapeutics has been rated by research analysts at B. Riley, BTIG Research, Citigroup, HC Wainwright, Oppenheimer, and Wedbush in the past 90 days.